Fairfax, VANCT05954312Now EnrollingIRB Ready

Advanced Solid Tumors Clinical Trial in Fairfax, VA

Access cutting-edge advanced solid tumors treatment through this clinical trial at a research site in Fairfax. Study-provided care at no cost to qualified participants.

Sponsored by Vividion Therapeutics, Inc.

Quick Self-Assessment

See if you qualify for this Fairfax location

Preparing your pre-screening questions…

Expert Care in Fairfax

Access advanced solid tumors specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced solid tumors treatment provided free

Apply for This Fairfax Location

Check if you qualify for this advanced solid tumors clinical trial in Fairfax, VA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Fairfax

    Convenient for VA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Fairfax site if eligible
  4. 4Begin participation

About This Advanced Solid Tumors Study in Fairfax

A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.

Sponsor: Vividion Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

for Parts 1 and 2:
Histologically or cytologically confirmed metastatic or unresectable solid tumor.
Measurable disease by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as assessed by the Investigator.
Have progressed on or after all prior standard-of-care therapies for metastatic disease.
Eastern Cooperative Oncology Group (ECOG) performance status ≤1.
Adequate organ and marrow function as defined in the protocol. Additional Key Inclusion Criteria for Part 2:
Participants with squamous non-small cell lung cancer (sqNSCLC) with or without nuclear factor erythroid 2-related factor 2 (NRF2 \[NFE2L2\]) and/or cullin 3 (CUL3) mutations.
Participants with advanced sqNSCLC must be refractory to or have progressed on or after a platinum-based doublet regimen and an immune checkpoint inhibitor.
Participants with advanced head and neck squamous cell carcinoma (HNSCC) must have received prior treatment with platinum-based chemotherapy, an immune checkpoint inhibitor (for tumors with known programmed death-ligand 1 \[PD-L1\] expression, microsatellite instability-high, or mismatch repair deficiency, and an anti-epidermal growth factor receptor agent) (Combination Expansion Cohort).
Participants with advanced esophageal squamous cell carcinoma (ESCC) must have received prior treatment with platinum-based chemotherapy, an immune checkpoint inhibitor (for tumors with known PD-L1 expression) (Combination Expansion Cohort).
Participants with a known driver mutation, including activating epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements, should have progressed after appropriate targeted treatment.
Participants with known human epidermal growth factor receptor 2 overexpression should have progressed after appropriate targeted treatment. Key

Exclusion Criteria

for Parts 1 and 2:
Participant is known to have a mutation that has no expectation of benefit from VVD-130037. Current such mutations include the following:
KEAP1 nonsense mutation (any position)
KEAP1 frameshift mutation (any position)
Any unresolved toxicity Grade ≥2 per CTCAE version 5.0 from previous anticancer treatment.
Current or prior treatment with anti-epileptic medications for the treatment or prophylaxis of seizures.
History of seizure or condition that may predispose to seizure.
History or presence of central nervous system (CNS) metastases or spinal cord compression.
Uncontrolled arterial hypertension despite optimal medical management.
Risk factors for abnormal heart rhythm/QT prolongation as defined in the protocol.
History of the following cardiac diseases: i) congestive heart failure (New York Heart Association \[NYHA\] Class \>II), ii) unstable angina, iii) new onset angina within past 6 months, iv) myocardial Infarction within the past 6 months, v) clinically significant arrhythmias within past 6 months.
Any prior toxicity (Grade 3 or 4) related to immunotherapy leading to treatment discontinuation (Combination Expansion Cohort)
Medical history of (noninfectious) pneumonitis/interstitial lung disease (ILD), drug induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active pneumonitis/ILD (Combination Expansion Cohort)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fairfax?

Yes, this clinical trial (NCT05954312) has an active research site in Fairfax, VA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Solid Tumors Treatment Options in Fairfax, VA

If you're searching for advanced solid tumors treatment options in Fairfax, VA, this clinical trial (NCT05954312) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fairfax research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced solid tumors clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Fairfax, VA

See all advanced solid tumors clinical trials recruiting in Fairfax — not just this study.

Browse Advanced Solid Tumors Trials in Fairfax →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAlzheimers Disease TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Fairfax?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Fairfax, VA